FANJ
GYRE icon

Financial Architects (New Jersey)’s Gyre Therapeutics GYRE Stock Holding History

Financial Architects (New Jersey)’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-147
Closed -$9K – 1310
2019
Q1 		$9K Hold
147
– – ﹤0.01% 1108
2018
Q4 		$9K Sell
147
-66
-31% -$4.87K ﹤0.01% 1015
2018
Q3 		$17K Buy
213
+106
+99% +$8.4K ﹤0.01% 966
2018
Q2 		$9K Buy
107
+27
+34% +$4.74K ﹤0.01% 1013
2018
Q1 		$15K Buy
+80
New +$14.9K ﹤0.01% 965

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Financial Architects (New Jersey)'s GYRE Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Gyre Therapeutics (GYRE) in Q2 2019, closing a stake of 147 shares — an estimated $9K sold.

Financial Architects (New Jersey) first reported a position in GYRE in Q1 2018 and held it in 5 quarters. The position peaked at $17K in Q3 2018. 49 funds tracked by Wall St. Rank hold GYRE as of Q2 2019.

  • Financial Architects (New Jersey) reported no remaining Gyre Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 147 Gyre Therapeutics shares in Q2 2019, an estimated $9K.
  • Financial Architects (New Jersey) first reported a position in Gyre Therapeutics in Q1 2018 and held it in 5 quarters.
  • Financial Architects (New Jersey)'s Gyre Therapeutics position peaked at $17K in Q3 2018.
  • 49 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.